Compare ALRS & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALRS | IVA |
|---|---|---|
| Founded | 1879 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 751.6M | 883.8M |
| IPO Year | 2019 | N/A |
| Metric | ALRS | IVA |
|---|---|---|
| Price | $31.11 | $3.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $25.40 | $16.20 |
| AVG Volume (30 Days) | 272.1K | ★ 1.3M |
| Earning Date | 04-29-2026 | 03-30-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.42 | N/A |
| Revenue Next Year | $4.68 | $751.20 |
| P/E Ratio | $34.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.26 | $2.94 |
| 52 Week High | $31.86 | $7.98 |
| Indicator | ALRS | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 68.85 | 47.55 |
| Support Level | $23.13 | $3.79 |
| Resistance Level | N/A | $4.67 |
| Average True Range (ATR) | 0.71 | 0.18 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 69.59 | 90.32 |
Alerus Financial Corp is a financial holding company registered in the United States. The company operates in four segments: Banking, Retirement & Benefit Services, Wealth Management, and others. The company provides various banking services such as checking, debit cards, savings, current deposits, loans and advances, online banking, mobile banking, private banking, payment solutions, and other business products. Additionally, the company provides mortgage loans, retirement planning solutions, individual retirement accounts, retirement plan advisory services and wealth management services, including retirement plans, and fiduciary services. The company's revenue mainly consists of interest income, commission, management fees, and other income.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.